Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 326

Results For "AI"

8414 News Found

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
News | July 29, 2024

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024


USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru
News | July 29, 2024

USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru

The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants


Max Healthcare CMD Abhay Soi recognised as one of the highest individual tax payers in India
People | July 27, 2024

Max Healthcare CMD Abhay Soi recognised as one of the highest individual tax payers in India

Abhay Soi, who had paid an income tax of approximately Rs 400 crore in the assessment year 2023-24 has been recognised as the “Top Individual tax payers having gross tax payable > Rs 10 Lakhs"


Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power
News | July 26, 2024

Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power

The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants


Cupid widens e-Commerce presence on leading Indian platforms
News | July 26, 2024

Cupid widens e-Commerce presence on leading Indian platforms

This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide


Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr
News | July 26, 2024

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands


Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate
Clinical Trials | July 26, 2024

Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis


Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr
News | July 26, 2024

Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr

Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024


European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B
Drug Approval | July 26, 2024

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)